linjc16/ctgov huggingface dataset:
Intestinal Microbiota and Antimicrobial Resistance in Hong Kong Residents After Travel

Study Overview
=================
Brief Summary
-----------------
International travel is well reported to be associated with acquisition of multidrug-resistant organisms, however, the impact of colonization of these multidrug-resistant organisms is currently uncertain. As colonization of multidrug-resistant organisms had been demonstrated to be associated with distinct intestinal microbiota composition and travellers constitute a generally healthy population with minimal antibiotics exposure; by evaluating serial stool samples before and after travel, the investigators can delineate a potential causal relationship between host intestinal microbiota and subsequent risk of acquisition of multidrug-resistant organisms.

Official Title
-----------------
Changes in Intestinal Microbiota and Acquisition of Antimicrobial Resistance in Hong Kong Residents After Travel

Conditions
-----------------
Antimicrobial Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 18 years or above Chinese ethnicity Planning to visit any places outside of Hong Kong within the next three months Able to provide informed consent Exclusion Criteria: Use of antibiotics within 4 weeks prior to the time of recruitment (Except for antimalarial prophylaxis) Hospitalization within 3 months Underlying gastrointestinal diseases, including gastrointestinal malignancy, inflammatory bowel disease, resection of small or large bowel Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Travellers<br>Adults planning for travel | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients acquiring intestinal colonization of ESBL-producing Enterobacteriaceae | Intestinal colonization of ESBL-producing Enterobacteriaceae is defined as the presence of ESBL in Enterobacteriaceae identified in the post-travel stool samples, in patients without these organisms detected in their stool samples before travel. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients acquiring intestinal colonization of carbapenem-resistant Enterobacteriaceae | Intestinal colonization of carbapenem-resistant Enterobacteriaceae is defined as the presence of carbapenem-resistant Enterobacteriaceae identified in the stool samples, in patients without these organisms detected in their stool samples before travel. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intestinal microbiota, Antimicrobial resistance
Assessing the Level of Disability and Fear Avoidance Beliefs in Bankers of Karachi

Study Overview
=================
Brief Summary
-----------------
An observational study will be conducted to determine the level of pain and disability among bankers working in different banking setups for past 2 years by using Neck Disablity Pain Index and Fear Avoidance Belief Questionnaire. the participant will be recruted fromdifferent private and public banking sectors of Karachi, including Habib bank limited, Silk bank,JS bank and other.

Detailed Description
-----------------
A cross-sectional study with a total sample size of 100 participants will be recruited for the purpose of the survey. The participants will be given Neck Disability Pain Index Questionnaire and Fair avoidance belief Questionnaire in order to determine the level of pain and disability among bankers who are performing their duties in bank from atleast two years.

Official Title
-----------------
Assessing the Level of Disability and Fear Avoidance Beliefs in Bankers of Karachi

Conditions
-----------------
Neck Pain

Intervention / Treatment
-----------------
* Other: Neck Disability Pain Index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bankers with neck pain Exclusion Criteria: neck surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Neck Disability Pain Index|Single time collection of the data|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Pain Index | Quantification of pain and disabilty | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fear Avoidance Belief, musculoskeletal Disorders, neck pain
EEG Diagnostic for Repetitive Sub-concussive Head Impacts

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a diagnostic algorithm to help with the detection, diagnosis, and monitoring of sub-concussive head impacts.

Detailed Description
-----------------
This prospective study will investigate the potential effects of soccer ball heading on EEG and oculomotor measurements.

Official Title
-----------------
Development of an EEG Diagnostic for Repetitive Sub-concussive Head Impacts: A Feasibility Study

Conditions
-----------------
Concussion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 - 38 years of age. Have at least 1 year of experience playing soccer. Played soccer within the prior year. Head soccer ball during practice and/or games. Exclusion Criteria: Subjects with a history of TBI during the prior 12 months. History of moderate or severe Traumatic Brain Injury (TBI). History of seizures. Medical or psychiatric history the precludes participation. Currently receiving treatment in another research study. History of a condition with vestibular, ocular, or vision dysfunction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Heading Group only<br>Subjects will perform a ball-passing task using their head | |
| Kicking Group then Heading Group<br>Subjects will perform a ball-passing task with their foot first, then will perform a ball-passing task using their head | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in EEG Signals | Sensitivity of a machine-learning based algorithm containing changes in EEG signals and functional connectivity for distinguishing research participants who headed a soccer ball from research participants who kicked the ball. A leave-one-out cross validation approach will be used. | Baseline, 45 minutes post-heading, 24 hours post-heading | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Eye Tracking Parameters | Sensitivity of a model containing changes in eye tracking measurements for distinguishing research participants who headed a soccer ball from research participants who kicked the ball. | Baseline, 45 minutes post-heading, 24 hours post-heading | 
| Change in King-Devick Testing Scores | Sensitivity of a model containing changes in King-Devick test scores for distinguishing research participants who headed a soccer ball from research participants who kicked the ball. | Baseline, 45 minutes post-heading, 24 hours post-heading |
Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this single-center, double-blinded randomized control trial with prospective data collection is to assess the ability of platelet rich plasma (PRP) treatment to reduce the level of pro-inflammatory synovial fluid biomarkers following an acute anterior cruciate ligament (ACL) tear. The study will collect and analyze synovial fluid of patients presenting with an acute anterior cruciate ligament (ACL) tear with a second synovial fluid sampling at the time of surgery. It will compare synovial fluid biomarker levels between those receiving an intra-articular Platelet Rich Plasma (PRP) injection versus an intra-articular saline injection serving as a control. Post-operative clinical outcomes will also be assessed, including post-operative pain levels, incidence of post-operative knee stiffness and patient reported outcome scores.

Official Title
-----------------
Can Platelet Rich Plasma Reduce the Level of Pro-Inflammatory Synovial Fluid Biomarkers Following an Anterior Cruciate Ligament Tear

Conditions
-----------------
ACL - Anterior Cruciate Ligament Rupture, ACL Injury

Intervention / Treatment
-----------------
* Biological: Platelet Rich Plasma
* Other: Saline Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients have suffered an acute ACL tear (initial presentation within 7 days of injury) with or without an associated meniscus injury Patient must undergo ACL reconstruction surgery Exclusion Criteria: Mentally impaired (e.g, Alzheimer's subjects, dementia, etc.) Younger than 18 years of age Patients who have a multiligamentous injury Patients with underlying inflammatory arthropathies Previous ACL injury and/or reconstruction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Platelet Rich Plasma<br>Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system. | Biological: Platelet Rich Plasma<br>* Pure PRPII®, leukocyte-poor, platelet rich plasma<br>|
| Placebo Comparator: Saline Placebo<br>Unmarked syringe with 5 ml of saline | Other: Saline Placebo<br>* saline solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| synovial fluid biomarker levels | The synovial fluid samples obtained at the two time points will be analyzed for the presence of 20 biomarkers using a multiplex bead assay (Milliplex®, Millipore, Billerica MA) | 2 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Platelet Rich Plasma
Circulating Levels of Pealbumin in Relation to Overweight or Obesity

Study Overview
=================
Brief Summary
-----------------
The study was aimed to investigating the relationship between circulating level of prealbumin and parathormone (PTH), triglycerides and triiodothyronine (FT3) in overweight and obese subjects (BMI≥25 Kg/m2)

Official Title
-----------------
Independent Relationship Between Prealbumin and Circulating Levels of Parathormone Triglycerides and FT3 in Subjects With Overweight or Obesity

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overweight or obesity (BMI> 25 Kg/m2) Exclusion Criteria: Any kind of drug Hypertension Endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), Chronic inflammatory diseases Renal failure Liver failure Angina pectoris Myocardial infarction and heart failure Genetic heart diseases Thrombocytopenias
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prealbumin | Prealbumin (g/L) concentration in serum | baseline | 
| Free Triiodothyronine (FT3) | FT3 (pg/mL) concentration in serum | baseline | 
| Parathormone (PTH) | PTH (pg/mL) concentration in serum | baseline | 
| Triglycerides | Triglycerides (mg/dl) concentration in serum | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Height | Height in meters | baseline | 
| Weight | Weight in kilograms | baseline | 
| Body mass Index (BMI) | BMI (kg/m^2) | baseline |
Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether preventative placement of a removable oesophageal stent reduces the rate of scar tissue, or stricture formation after removing the precancerous or early cancerous Barrett's mucosa by Endoscopic Mucosal Resection (EMR). The stent will be placed 10-14 days after initial EMR. The stent will then be removed 8 weeks later by repeat Endoscopy. Patients will be followed up weekly following insertion of the oesophageal stent.

Official Title
-----------------
Fully, Coated, Removable, Self-expanding Oesophageal Stents for the Prevention of Oesophageal Stricture Following Endoscopic Mucosal Resection of Short Segment Barrett's With High Grade Dysplasia and Early Cancer.

Conditions
-----------------
Constriction, Pathological

Intervention / Treatment
-----------------
* Device: Fully coated, removable , self-expanding oesophageal stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with short segment Barrett's Oesophagus with high grade dysplasia or early cancer, having circumferential EMR to achieve complete Barrett's excision. Aged 18-75 years old Biopsy proven to be Barretts with HGD or EAC The absence or lymph node involvement Short segment <3cm of Barretts Oesophagus. Exclusion Criteria: Women who are pregnant and the human foetus Children and/or young people <18 years People with an intellectual or mental impairment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oesophageal Stents<br>Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent. | Device: Fully coated, removable , self-expanding oesophageal stent<br>* Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in Stricture Formation | Initial evaluation of Dysphagia score which is used to assess the stricture formation prior to EMR. Followed by weekly phone calls to assess ability to swallow liquids and food. | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stricture, Dysphagia
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.

Detailed Description
-----------------
The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory. The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.

Official Title
-----------------
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected or confirmed diagnosis of lung cancer undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis. Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease Patient must be at least 18 years of age Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database. Exclusion Criteria: Patient pathology shows benign pathology for sample submitted Patient is not indicated to receive chemotherapy for their disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor size | Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start. Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chemosensitivity, Lung cancer
Observational Study on Pregnant Women With Chronic Hepatitis B and Their Infants

Study Overview
=================
Brief Summary
-----------------
The study was conducted to observe the clinical features during pregnancy in women with chronic hepatitis B virus infection and mother-to-child transmission of hepatitis B virus.

Official Title
-----------------
Epidemiological Study on Clinical Features of Chronic Hepatitis B Virus Infection During Pregnancy and Hepatitis B Virus Mother-to-child Transmission (Shield Study Phase Ⅰ)

Conditions
-----------------
Hepatitis B, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestation of 4-32 weeks HBsAg+ > 6 months, HBeAg+/- Informed consent signed voluntarily Good compliance and able to be followed up as planned Exclusion Criteria: Coinfection with hepatitis C virus or human immunodeficiency virus; Comorbidities of other severe conditions that hinder compliance with follow ups and because of that, the subjects are anticipated to be unable to complete the project.; Unable or unwilling to use mobile health tools.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of mother-to-child transmission |  | Infants from 7 to 12 months of age | 
| Rate of hepatitis flare during pregnancy and postpartum |  | up to postpartum weeks 6-8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic hepatitis B, Mother-to-child transmission
UEMR for Medium-sized Pedunculated Colon Polyps

Study Overview
=================
Brief Summary
-----------------
Underwater EMR (UEMR) is an emerging technique for endoscopic resection. The purpose of this research is to observ wether the UEMR for medium-sized pedunculated polyps is safe and effective.

Official Title
-----------------
The Use of Underwater Endoscopic Mucosal Resection for Medium-sized Pedunculated Colon Polyps: A Prospective Observational Study

Conditions
-----------------
Colon Polyp

Intervention / Treatment
-----------------
* Procedure: UEMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age between 18-75 years old with pedunculated colonic polyps (measuring between 10 and 20mm), who willing to participate in this study. Exclusion Criteria: pregnancy, inflammatory bowel disease, familial polyposis the use of anticoagulant therapy or antiplatelet therapy the absence of informed patient consent. Polyps showing signs of deep submucosal invasion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| UEMR<br> | Procedure: UEMR<br>* (1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of bleeding | the bleeding was defined as the active hemorrhage lasted for ≥ 30 s or other condition requires immediate intervention. | 1 Day of colonoscopy |